Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Date of authorisation: 19/06/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Imaavy, nipocalimab, Date of authorisation: 28/11/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Date of authorisation: 21/11/2012, Revision: 40, Status: Authorised

Orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate Treatment of Charcot-Marie-Tooth disease, 14/12/2015 Positive

Human medicines European public assessment report (EPAR): Isembyld, apitegromab, Status: Application withdrawn

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive